Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
Last updated: October 16, 2026 Capital paid for AI drug discovery three ways in one day: City Therapeutics priced an upsized $200.0 million IPO at
Last updated: October 15, 2026 The FDA approved ImmunityBio’s Anktiva with BCG for BCG unresponsive, high grade, papillary only bladder cancer on October 14 by
Last updated: October 14, 2026 Johnson & Johnson grew third quarter sales 5.9% to $25.4 billion and raised 2026 guidance, yet the stock settled 5.7%
Last updated: October 13, 2026 Four positive readouts landed on October 12: First Tracks’ ANB033 protected celiac patients through a gluten challenge, Mirum’s Livmarli met
Last updated: October 12, 2026 Merck’s remigromig met its noninferiority endpoint in the pivotal BRUNELLO trial, gaining 9.1 letters at one year against ranibizumab’s 11.8,
Last updated: October 9, 2026 argenx discontinued its Phase 3 UNITY study of efgartigimod SC in Sjögren’s disease for futility on the same morning FB102
Last updated: October 8, 2026 PhRMA sued in federal court on October 7 to block Medicare’s GLOBE most favored nation pricing model before its January
Last updated: October 7, 2026 ArriVent’s firmonertinib missed FURVENT’s primary endpoint in first line EGFR exon 20 insertion lung cancer (hazard ratio 0.75, p=0.0654), sending
Last updated: October 6, 2026 Vaxcyte’s 31 valent pneumococcal vaccine VAX-31 met every prespecified primary immunogenicity endpoint in its pivotal adult Phase 3, OPUS-1, while
Last updated: October 5, 2026 Novartis licensed Abogen’s mRNA encoded T cell engager for $575 million upfront and up to $7.8 billion total, CSL paid
